Wolf & Company brings restaurant, market to the 606
With the opening of Wolf & Company at Western and the 606, serviceberries are no longer the tastiest treats on the Bloomingdale Trail.
Why it matters: The dual-level bar, restaurant, market and cafe with a handsome trail-hugging patio takes 606 enjoyment to a new level.
Dig in: During a recent media preview, we loved the wood-fire pizza ($20-$29), golden beets ($13) and spicy Buffalo wings ($17), but the dirty martini salad ($18) was missing some creamy balance. Roast chicken, steaks and ribs round out the menu.
Fans of sister spots, Gretel and Little Bad Wolf, will be happy to find a juicy, perfectly stacked cheeseburger ($24) that lives up to the family name.
Drink up: The bar offers a wide array of cocktails ($16) and pints of local and imported craft ciders and beer ($8-$10).
Cafe patrons can sip brews from Rare Tea Cellar, Rishi, Hexe and Big Shoulders.
Shop talk: The downstairs grocery store features food-centric gifts, deli items, local artisan products and even a butcher.
Watch out: Snag one of the comfy outdoor tables and take in some great people watching as 606 users stream past on bikes and feet.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
ALUULA Reports Second Quarter 2025 Financial Results
From windsports to wind power- ALUULA prepares for broader market growth Victoria, British Columbia--(Newsfile Corp. - June 25, 2025) - ALUULA Composites Inc. (TSXV: AUUA) ("ALUULA" or the "Company") today reported its financial results for the three and six month periods ended April 30, 2025 ("Q2 2025" and "YTD Q2 2025" respectively). All currency amounts noted are in Canadian dollars. Building on momentum from its first quarter, the Company continued to progress against its fiscal 2025 strategic initiatives during Q2 2025. ALUULA reported ongoing diversification of its customer base and sales pipeline, leveraged its expertise in kite design to advance leads in the wind power vertical market, and maintained gross margins within its target range. "This quarter is pivotal for us as we're turning towards a higher growth phase for the company," said Sage Berryman, President & CEO. "Our start in windsports has laid a strong technical and commercial foundation and we are building on that momentum to move into verticals such as wind power and beyond. We see the outlines of a future defined by high growth, diversification and broader market relevance. We are aligning our product innovation, our continued focus on circularity, our team, and partnerships to meet our growth potential." Key Q2 2025 Highlights Sales for Q2 2025 were $1,573,677 compared to $1,403,151 for the three-month period ended April 30, 2024 ("Q2 2024"), which represents a $170,526 or 12% increase. Sales increased across both of ALUULA's sales channels, with Performance Outdoor increasing by $113,935 and Commercial Industrial increasing by $56,591. The Company also continued to make progress against its customer diversification goals by: Reducing sales concentration with the windsport vertical market to 76% compared to 96% in Q2 2024. Continuing to diversify the sales pipeline with 100% of prototype size orders being generated by customers outside the windsport vertical market, compared to 94% in Q2 2024. Gross margins for Q2 2025 were 43% compared to 40% in Q2 2024, which is within the Company's expected range of 40%-45%. Operating expenses were $881,843 in Q2 2025 compared to $1,556,493 in Q2 2024 representing a decrease of $674,650. Operating expenses in Q2 2024 were higher due to costs incurred to effect organizational changes including $390,000 in severance payments and $50,000 in general & administration ("G&A") costs resulting from the write off of patents and trademarks no longer needed to support the Company's future growth. Also contributing to higher G&A costs in Q2 2024 were warranty provisions recorded for older materials with higher-than-average warranty rates. Other Income was $15,540 in Q2 2025 compared to $752,379 in Q2 2024 representing a decrease of $736,839. In Q2 2024, Other Income included a fair value adjustment of $749,391 associated with the Company's investment in Xlynx Materials Inc. common shares (the "Xlynx Shares"). The fair value adjustment was based on the sale price negotiated for the Xlynx Shares in a May 2024 purchase and sale agreement. Net and comprehensive loss from Ocean Rodeo's discontinued operations was $60,936 Q2 2025 compared to a net and comprehensive loss of $394,680 in Q2 2024 representing a decrease of $333,744. This decrease is a direct result of cost cutting measures implemented in April 2024 after the decision was made to discontinue Ocean Rodeo's operations. Key YTD Q2 2025 Highlights Sales for YTD Q2 2025 were $2,835,206 compared to $3,400,430 during YTD Q2 2024, which represents a decrease of $565,224 or 17%. The decrease in YTD Q2 2025 sales is due to timing of receipt of windsport customer orders, which varied significantly across fiscal 2024 quarters and are expected to be more consistent throughout fiscal 2025, a trend that is holding true through the six-month period ending April 30, 2025. Gross margins for YTD Q2 2025 were 43%, which was consistent with the YTD Q2 2024 period and within the Company's expected range of 40%-45%. Operating expenses were $1,701,373 in YTD Q2 2025 compared to $2,239,525 in Q2 2024 representing a decrease of $538,152. Operating expenses in YTD Q2 2024 were higher due to costs incurred to effect organizational changes detailed earlier in this press release. The Company also reported a $106,723 reduction in marketing expenses in YTD Q2 2025 due to the decision not to exhibit at two tradeshows in Germany that were attended in YTD Q2 2024. Net and comprehensive loss from Ocean Rodeo's discontinued operations was $66,331 in YTD Q2 2025 compared to a net and comprehensive loss of $741,237 in YTD Q2 2024 representing a decrease of $674,906. This decrease is a direct result of cost cutting measures implemented in April 2024 after the decision was made to discontinue Ocean Rodeo's operations. Outlook The Company continues to work with its growing list of brand partners, developing products that are lighter, stronger, and recycle-ready. These partnerships are built on the mutual understanding that performance and circularity can be synonymous in the outdoor industry and beyond. The products that are born from these partnerships work to change their respective industries for the better. The Windsport and other Performance Outdoor categories are still the core drivers of ALUULA's growth as more companies move from concept into commercialization, launching new ALUULA-enabled products. Collaborative research and development programs with other industrial partners, such as Michelin Inflatable Solutions and AirSeas, continue to advance the materials' development as these opportunities move towards commercial application. While these existing opportunities continue to progress, the Company is also prioritizing proactive sales outreach in large and growing markets where strong product fit exists and ALUULA's high-performance materials enable uses not possible with incumbent materials. This includes focusing on Commercial Industrial applications such as renewable energy sources (wind power is one example, with the current drive towards decarbonization of the shipping industry) and defense applications (such as ultra-light and ultra-strong sustainable portable shelters, particularly for extreme cold environments). With the Company's corporate foundation now stabilized, ALUULA is focused on key areas including sales pipeline expansion, product innovation, and circularity. The Company has prioritized these areas as well as continued improvements to the patented manufacturing process, as it expects them to contribute to improved efficiencies and profitability. All of these operational aspects will work together to achieve ALUULA's mission, which is to help instigate a global composite textile revolution and prove that high-performance and circularity are synonymous. Financial Statements and Management's Discussion and Analysis This earnings press release should be read in conjunction with ALUULA's unaudited interim condensed consolidated financial statements for the six months ended April 30, 2025 and the related management discussion and analysis, which can be found on ALUULA's website and its issuer profile on the System for Electronic Document Analysis and Retrieval Plus at About ALUULA Composites ALUULA is an ultra-light, high performance and recycle-ready composite materials brand that enhances the performance of outdoor gear. Proudly owned and manufactured on the Canadian west coast, ALUULA's innovation is driven by a deep understanding that equipment does not need to sacrifice performance for sustainability. ALUULA's materials are known for their unique construction capabilities and their ability to make products lighter, stronger, and more sustainable. | (TSXV: AUUA) On behalf of the Board of Directors,Sage BerrymanChief Executive Officer1-888-724-2470 For ALUULA investor inquiries, please contact: 1-888-724-2470, ext. 4 IR@ For ALUULA media relations, please contact: media@ ALUULA's Brand Partners The term "brand partners" does not refer to formal partnerships with our customers. The term refers to marketing relationships with our customers who use ALUULA's technology as a brand ingredient in their products. TSX Venture Exchange Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements The information in this news release includes certain information and statements about management's view of future events, expectations, plans, and prospects that constitute forward-looking statements, including, but not limited to: the Company's list of brand partners growing; the Company's advancement of its materials development; the Company's future focus on Commercial Industrial and defense applications; ; the Company achieving its mission. These statements are based on assumptions subject to significant risks and uncertainties as described in the Company's management discussion and analysis. Because of these risks and uncertainties and as a result of a variety of factors, including the timing and receipt of all applicable regulatory, corporate third-party approvals, the actual results, expectations, achievements, or performance may differ materially from those anticipated and indicated by these forward-looking statements. Although the Company believes that the expectations reflected in forward-looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statement will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Hamilton Spectator
14 minutes ago
- Hamilton Spectator
PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares
TORONTO, June 25, 2025 (GLOBE NEWSWIRE) — Psyence Group Inc. (CSE: PSYG) ('Psyence' or the 'Company'), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, is pleased to announce an update to its previously announced non-brokered private placement (the 'Offering') of common shares in the capital of the Company (the 'Common Shares'). Pursuant to the Offering, the Company has raised gross proceeds of C$600,000 split into two tranches. Tranche 1 closed today, and the Company has issued an aggregate of 4,760,000 Common Shares at a price of C$0.10 per Common Share for gross proceeds of C$476,000. Tranche 2 is anticipated to close on or about July 4, 2025 for the remaining gross proceeds of C$124,000. The Offering was originally announced on June 18, 2025. The net proceeds of the Offering will be used for general working capital purposes. The Offering was completed pursuant to the prospectus exemption available under Section 2.3 of National Instrument 45-106 – Prospectus Exemptions (the 'accredited investor' exemption) and other available exemptions under applicable securities laws. All securities issued in connection with the Offering are subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable Canadian securities laws. In the event that the Company undertakes a transaction that constitutes a fundamental change, change of business, reverse takeover, or other reviewable transaction as defined under applicable securities laws and policies of the Canadian Securities Exchange, or raises additional funds through a public offering, private placement, or other capital raise involving equity or equity-linked instruments, the resale restrictions may extend beyond four months and one day following the completion of such transaction. There can be no assurance that any transaction will be identified or completed, and the Company may reallocate the use of proceeds depending on evolving business needs and market conditions. ABOUT PSYENCE GROUP: Psyence is a life science biotechnology company listed on the Canadian Securities Exchange (CSE: PSYG), with a focus on natural psychedelics. Psyence works with nature-derived psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. Our name 'Psyence' combines the words psychedelic and science to affirm our commitment to producing psychedelic medicines developed through evidence-based research. Informed by nature and guided by science, Psyence works to develop advanced nature-derived psilocybin products for clinical research and development. Contact Information Learn more at Email: ir@ Media Inquiries: media@ General Information: info@ Phone: +1 416-477-1708 FORWARD LOOKING STATEMENTS: Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information. These risks and uncertainties include the successful closing of the second tranche of the Offering, the successful deployment of the Offering proceeds and the identification of opportunities in the market. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements. The Company makes no medical, treatment or health benefit claims about the Company's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company's performance and operations.
Yahoo
20 minutes ago
- Yahoo
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
CUPERTINO, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ('Reviva' or the 'Company'), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it intends to offer shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in a public offering. All of the securities to be sold in the offering are to be offered by Reviva. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering. The Company currently intends to use the net proceeds from the offering to fund research and development activities and for working capital and other general corporate purposes. The securities will be offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-276848), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the 'SEC') on February 2, 2024, and declared effective by the SEC on February 13, 2024. A preliminary prospectus supplement will be filed with the SEC and will be available on the SEC's website at Copies of the preliminary prospectus supplement and accompanying base prospectus, when available, may be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@ This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Reviva Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva's pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries. Forward-Looking Statements This release contains 'forward-looking statements' made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as 'believes,' 'expects,' 'anticipates,' 'intends,' 'will,' 'may,' 'should,' or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, risks associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering and uncertainties related to the size, timing, completion, and use of proceeds from the proposed offering. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company's business in general, please refer to the Company's prospectus supplement to be filed with the SEC, and the documents incorporated by reference therein, including the Company's Form 10-K for the year ended December 31, 2024 and Form 10-Q for the quarter ended March 31, 2025. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. REVIVA CONTACTS: Corporate Contact:Reviva Pharmaceuticals Holdings, Bhat, Investor Relations Contact:LifeSci Advisors, LLCPJ Kelleherpkelleher@
